Burden of fungal disease for 13 countries published in Journal of Fungi
June 28 2018
The Journal of Fungi has recently published a series of papers (edited by Professors Malcolm Richardson and Donald Cole) estimating the fungal disease burden for 13 more countries: Colombia, Uruguay, Argentina, Burkina Faso, Cameroon, Mozambique, Malawi, Jordan, Romania, Serbia, Norway, Kazakhstan and Malaysia.
Two point-of-care tests for invasive aspergillosis launched
June 21 2018
Two companies - IMMY and ISCA Diagnostics - have launched point-of-care ('bedside') testing for invasive aspergillosis, which should help to reduce mortality rates by shortening the time to diagnosis and treatment initiation.
Review of epidemiological data for onychomycosis caused by Aspergillus spp.
June 04 2018
A recent review of 42 epidemiological studies by Dr Felix Bongomin and colleagues showed that the causative agent of onychomycosis (nail infection) was Aspergillus spp. in 1-35% of cases overall, but more frequently among the elderly and those with diabetes (up to 71%). Toenails were affected 25x more often than fingernails.
Science magazine special issue highlights antifungal resistance
May 25 2018
A special issue of Science magazine entitled 'The Rise of Resistance' raises the profile of one of the most urgent challenges to world health: the increase in antifungal-resistant pathogens and a lack of novel antifungals in the pipeline to cope with them.
New 3D model of squalene epoxidase may explain mechanism of terbinafine resistance
May 23 2018
Dermatophytes such as Trichophyton are commonly resistant to the allylamine antifungals (terbinafine, naftifine) used to treat them. Dr Rudramurthy and colleagues in India found that around 1 in 8 clinical isolates were resistant to these drugs, and 30% of them had a Phe397Leu mutation in squalene epoxidase. As this mutation sits in the enzyme's binding site, it is a plausible mechanism for resistance.